eISSN: 1689-3530
ISSN: 0867-4361
Alcoholism and Drug Addiction/Alkoholizm i Narkomania
Bieżący numer Archiwum Online first O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
vol. 35
Poleć ten artykuł:
Opis przypadku

Nierozpoznana encefalopatia Wernickego. Opis przypadku majaczenia hiperaktywnego

Autumn Loichle
Amira Athanasios
Tyler Santos
Adriana Fitzsimmons

Hackensack Meridian Jersey Shore University Medical Center, NJ, USA
Alcohol Drug Addict 2022; 35 (1): 67-72
Data publikacji online: 2022/07/10
Plik artykułu:
- AIN-Loichle.pdf  [0.31 MB]
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Wernicke’s encephalopathy (WE) is an acute, possibly reversible state primarily due to loss of thiamine in the mammillary bodies of the limbic region as well as the thalamus, hypothalamus, and periaqueductal areas of the brain. WE can be observed in nearly 3% of the general population in the Western World and studies show prevalence ranging from 13 to 60% in patients with significant alcohol use [1, 2]. However, it should be considered that there has been limited data and research completed within recent years to reflect updated prevalence of WE. WE can sometimes be confused with alcohol intoxication or withdrawal or head injury due to the mental confusion, gait ataxia and ophthalmoplegia triad of classic symptoms. Consequently, the similarity in alcohol abuse patients’ clinical presentation can make it difficult to diagnose and is often clinically under-recognised, resulting in underutilised thiamine treatments in at-risk patients. WE is a medical emergency and, if left untreated or treated inappropriately with either low doses of thiamine or oral thiamine, it may result in life-threatening and irreversible neurological damage and functional impairment known as Korsakoff syndrome (KS). The progression of untreated WE to the chronic phase of disease known as KS is also termed as “Wernicke-Korsakoff” syndrome (WKS). While parenteral thiamine is the mainstay of treatment for Wernicke’s encephalopathy, there is little consensus on best dosage, duration or route. The following article presents a patient diagnosed with Wernicke’s encephalopathy and summarises the literature on best treatment for WE.


We present the case of a male in his 70s with a medical history significant for alcohol use disorder, hypertension, chronic obstructive pulmonary disorder and cerebrovascular accident in 2019, who was admitted to hospital with dizziness and his treatment was complicated by alcohol withdrawal and worsening altered mental status with agitation.
Additionally, a history of alcohol abuse, between 4-12 cans of beer daily, reduced in frequency to one to two beers daily two months ago, was revealed. Further information provided revealed recent changes in his behaviour including lack of interest in engaging with family, becoming less sociable overall and easily angered, raising his voice and using vulgar language, which was reportedly out of character. The patient has had also poor oral intake and had stopped eating over the past two weeks. Collateral endorsed worsened behaviour patterns with increased irritability over the past few months and strange eye movements over the past week, which worsened over the past two days. On interview, the patient lacked insight into his condition demonstrated by not being able to recount the events leading to his hospitalisation and to identify his current condition. Throughout the interview, the patient appears to be disoriented and was uncooperative with psychiatric evaluation, stating that he only wanted to rest and sleep. Upon further questioning, the patient demonstrated intermittent verbal agitation, often yelling at staff that he wanted to exit the room. The patient also demonstrated impaired short term memory as he was unable to recall his treatment team and medical recommendations throughout his hospital stay despite having a consistent care team.
At the physical exam, the patient was irritable and could not tolerate interview questions. The patient was oriented to people, but not time or place. Speech was low in volume and slightly slurred with poor intonation. His thought process was goal directed, there were no overt delusions expressed, and short term memory was impaired as demonstrated by being unable to recall either medical recommendations or his care team. According to collateral information prior to the examination, the patient was seen reaching out for items that were not physically present though there were no overt observed or reported internal auditory or visual stimuli during the hospital stay. Patient denies suicidal and homicidal ideation. Horizontal nystagmus with fixed gaze and frequent upward gaze were noted at the examination. Computed tomography (CT) and magnetic resonance imaging (MRI) showed white matter disease most consistent with chronic small vessel ischemic change, and chronic right occipital lobe infarct without evidence of acute infarct or haemorrhage.
The consulting psychiatry team diagnosed WE. The clinical triad of confusion, ataxia, and ocular motor dysfunction was observed as demonstrated by collateral information that the patient had acutely unsteady gait on admission, disorientation and impaired attention at the mental status exam and during interview, and nystagmus and frequent upward gaze observed at the physical exam. There is also significant concern about malnutrition given that the patient had been refusing oral intake for twelve days. Thiamine 500 mg intravenous (IV) three times per day for three days was completed and continued on thiamine 250 mg IV. The patient was also started on Mirtazapine 15 mg per os nightly for appetite and sleep and Depakote sprinkles 125 mg every 8 hours as needed for agitation. Supportive therapy and reassurance were provided and the patient continued to be monitored by psychiatry, neurology and the primary medicine team.
Throughout the patient’s hospital course, the psychiatry team continued to see the patient daily to monitor signs and symptoms of WE. Patient tolerated psychiatric medications without any reported side effects. The patient self-reported that sleep and appetite continued to improve while in hospital. Hospital staff reported that the patient’s behaviour was improving overall, demonstrating less lability and psychomotor agitation overall. After three days of high dose IV thiamine, the neurology team documented they were unable to appreciate the previously observed nystagmus at the neurological exam.


Thiamine, also known as vitamin B1, is an essential vitamin that plays an important role in the proliferation of cellular energy from ingested food. The human body is unable to produce thiamine, therefore it must be obtained within the diet and can be found in breads, cereals, meats, among other foods [3]. Once ingested, thiamine is absorbed in the duodenum and then converted into thiamine pyrophosphate [4], its active form. This process requires magnesium as cofactor [3]. Absorption is completed through a carrier-mediated process that can be decreased by the use of alcohol due to alteration in the expression of receptors required for thiamine absorption [5]. Depending on the blood concentration of thiamine, transport across the blood-brain barrier can be either passive or active. Higher concentrations are transported by passive diffusion, while lower concentrations diffuse via active transport.
Thiamine deficiency occurs due to poor intake of vitamin-rich foods, impaired intestinal absorption, decreased liver storage capacity or alcohol-induced kidney damage and excessive loss associated with medical conditions [6]. Insufficient intake of thiamine leads to decreased activity of thiamine-dependent enzymes causing a compromise in cell respiration. Cell, specifically neuron, necrosis occurs as these have high thiamine demand and metabolic requirement. Studies have shown that cell death occurs in several areas of the brain including the thalamus, hippocampus, cerebellum, pons, brain regions around the ventricles and a few cortical areas [7, 8]. WE is a common neuropsychiatric syndrome that can be a result of alcohol-induced thiamine deficiency, commonly manifesting in those who have been diagnosed with alcohol-use disorder [9]. This has been known to be a main cause of WE in western countries, however, WE has also been identified in patients with malabsorption, malnutrition, gastrointestinal malignancies, dialysis, hyperemesis gravidarum, AIDS and bariatric surgery [10]. WE is classically known to present with the triad of gait ataxia, mental status changes and ophthalmoplegia. Nevertheless, this classic triad is present in only a fraction, with one study indicating less than a third, of cases making it difficult to distinguish between intoxication of alcohol, benzodiazepine withdrawal, sepsis, hypoxia, hypomagnesaemia and hepatic encephalopathy. Clinical diagnosis has been shown to be missing in up to 80% of cases [11].
WE is a medical emergency and if left untreated or treated inappropriately with either low doses of thiamine or oral thiamine, it may result in a life-threatening situation. Known as Wernicke-Korsakoff syndrome (WKS) or Korsakoff syndrome (KS), it is characterised by symptoms of opthalmoplegia, ataxia, acute confusion, unexplained hypotension, confabulations, memory disturbance, hypothermia and unconsciousness [6]. If WE is diagnosed early and treated appropriately, the symptoms can be reversed. However, if it progresses to KS, it has become a chronic condition characterised as irreversible. One study by Arts et al. concluded that there is currently no effective pharmacological treatment of KS, and emphasised the need to diagnose and treat WE adequately before it progresses [12]. Due to WE being largely caused by alcohol consumption, oral replacement of thiamine has been shown not to be an adequate treatment plan due to the reduced intestinal thiamine absorption [10]. Thiamine replacement, intravenously or intramuscularly, is the standard treatment. However, a consensus on optimal dose, frequency and duration has yet to be established [13, 14]. Several studies suggest using a high dose of IV thiamine treatment (500 mg) three times a day for 3-5 days to facilitate diffusion across the blood-brain barrier and restore vitamin status [13]. This is then is followed by an oral regimen of 250-1000 mg of thiamine until alcohol reduction or abstinence [15]. One study completed by Nakamura et al. illustrated that a high IV dose regimen was associated with a decrease in mortality [16]. Despite differences in recommendations in treatment and prevention for WE between clinicians, all have established that a high suspicion for WE warrants aggressive treatment in order to prevent a life-threatening situation in the clinical setting along with the high benefit-to-risk ratio of high dose thiamine.

Conflict of interest/Konflikt interesów

None declared./Nie występuje.

Financial support/Finansowanie

None declared./Nie zadeklarowano.


The work described in this article has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) on medical research involving human subjects, Uniform Requirements for manuscripts submitted to biomedical journals and the ethical principles defined in the Farmington Consensus of 1997.
Treści przedstawione w pracy są zgodne z zasadami Deklaracji Helsińskiej odnoszącymi się do badań z udziałem ludzi, ujednoliconymi wymaganiami dla czasopism biomedycznych oraz z zasadami etycznymi określonymi w Porozumieniu z Farmington w 1997 roku.


1. Torvik A, Lindboe CF, Rodge S. Brain lesions in alcoholics. A neuropathological study with clinical correlations. J Neurol Sci 1982; 56(2-3): 233-48. DOI: 10.1016/0022-510x(82)90145-9.
2. Naidoo DP, Bramdev A, Cooper K. Autopsy prevalence of Wernicke’s encephalopathy in alcohol-related disease. S Are Med J 1996; 86(9): 1110-2.
3. Osiezagha K, Ali S, Freeman C, Barker N, Jabeen S, Maitra S, et al. Thiamine deficiency and delirium. Innov Clin Neurosci 2013; 10(4): 26-32.
4. Frank LL. Thiamin in clinical practice. JPEN J Parenter Enteral Nutr 2015; 39(5): 503-20. DOI: 10.1177/0148607114565245.
5. Zhao R, Goldman ID. Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med 2013; 34(2-3): 373-85. DOI: 10.1016/j.mam.2012.07.006.
6. Praharaj SK, Munoli RN, Shenoy S, Udupa ST, Thomas LS. High-dose thiamine strategy in Wernicke-Korsakoff syndrome and related thiamine deficiency conditions associated with alcohol use disorder. Indian J Psychiatry 2021; 63(2): 121-6. DOI: 10.4103/psychiatry.IndianJPsychiatry_440_20.
7. Irle E, Markowitsch HJ. Widespread neuroanatomical damage and learning deficits following chronic alcohol consumption or vitamin-B1 (thiamine) deficiency in rats. Behav Brain Res 1983; 9(3): 277-94. DOI: 10.1016/0166-4328(83)90133-x.
8. Sullivan EV, Pfefferbaum A. Neuroimaging of the Wernicke-Korsakoff syndrome. Alcohol Alcohol 2009; 44(2): 155-65. DOI: 10.1093/alcalc/agn103.
9. Smith H, McCoy M, Varughese K, Reinert JP. Thiamine dosing for the treatment of alcohol-induced Wernicke’s encephalopathy: a review of the literature. J Pharm Technol 2021; 37(2): 107-13. DOI: 10.1177/8755122520962859.
10. Zafar A. Wernicke’s encephalopathy following Roux en Y gastric bypass surgery. Saudi Med J 2015; 36(12): 1493-5. DOI: 10.15537/smj.2015.12.12643.
11. Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J 2014; 44(9): 911-5. DOI: 10.1111/imj.12522.
12. Arts NJ, Walvoort SJ, Kessels RP. Korsakoff’s syndrome: a critical review. Neuropsychiatr Dis Treat 2017; 13: 2875-90. DOI: https://DOI.org/10.2147/NDT.S130078.
13. Nishimoto A, Usery J, Winton JC, Twilla J. High-dose parenteral thiamine in treatment of Wernicke’s encephalopathy: case series and review of the literature. In Vivo 2017; 31(1): 121-4. DOI: 10.21873/invivo.11034.
14. Isenberg-Grzeda E, Kutner HE, Nicolson SE. Wernicke-Korsakoff-syndrome: under-recognized and undertreated. Psychosomatics 2012; 53(6): 507-16. DOI: 10.1016/j.psym.2012.04.008.
15. Shoaib S, Hyder M, May M. An atypical long-term thiamine treatment regimen for Wernicke encephalopathy. Fed Pract 2020; 37(9): 405-9. DOI: 10.12788/fp.0029.
16. Nakamura ZM, Tatreau JR, Rosenstein DL, Park EM. Clinical characteristics and outcomes associated with high-dose intravenous thiamine administration in patients with encephalopathy. Psychosomatics 2018; 59(4): 379-87. DOI: 10.1016/j.psym.2018.01.004.
This is an Open Access journal distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode), allowing third parties to download and share its works but not commercially purposes or to create derivative works.
facebook linkedin twitter
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.